Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis
J J Kazama1, H Maruyama, F Gejyo
1Department of Medicine (II), Niigata University Medical School, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan.
Abstract:
Dialysis-related amyloidosis (DRA) is a common complication associated with long-term haemodialysis therapy. The elimination of beta2-microglobulin (beta2m), the major constituent of the amyloid fibrils in DRA, from circulation has been expected to bring some clinical benefit. Recently, a direct haemoperfusion method using selective beta2m absorption column to eliminate circulating beta2m has been introduced into clinical practice. According to a recently performed, prospective, multicentre study, joint pain, stiffness and daily activities were significantly improved in patients with established DRA after the introduction of selective beta2m absorption therapy. Meanwhile, although osteoarticular lesions progressed in the control group, there was no significant progression in the selective beta2m absorption therapy group. The absorptive affinity of the column for beta2m is not quite specific and therefore some other unknown uraemic toxins might be removed also. However, the improvement of joint pain and the ability to undertake daily activities showed reversed correlations against plasma beta2m clearance. Symptoms associated with the increased amount of extracorporeal circulation and increased economical burden are areas of concern for this therapy. In conclusion, selective beta2m absorption therapy was suggested to have the potential to ameliorate established DRA symptoms and simultaneously prevent its local development. The mechanism by which DRA symptoms are ameliorated remains obscure.
Insights
Selective beta2-microglobulin (beta2m) absorption therapy significantly improved joint pain and daily activities in patients with dialysis-related amyloidosis (DRA). This treatment also prevented the progression of osteoarticular lesions, offering a potential benefit for long-term dialysis patients.
Area of Science:
- Nephrology
- Biomedical Engineering
Background:
- Dialysis-related amyloidosis (DRA) is a frequent complication in patients undergoing long-term hemodialysis.
- Beta2-microglobulin (beta2m) is the primary component of amyloid fibrils in DRA.
- Eliminating circulating beta2m is hypothesized to offer clinical advantages for DRA patients.
Purpose of the Study:
- To evaluate the clinical efficacy of a novel direct hemoperfusion method using a selective beta2m absorption column.
- To assess the impact of beta2m elimination on established DRA symptoms and osteoarticular lesion progression.
Main Methods:
- A prospective, multicenter study was conducted involving patients with established DRA.
- Patients received direct hemoperfusion utilizing a selective beta2m absorption column.
- Clinical outcomes, including joint pain, stiffness, daily activities, and osteoarticular lesions, were monitored.
Main Results:
- Significant improvements were observed in joint pain, stiffness, and daily activity levels post-therapy.
- The beta2m absorption group showed no significant progression of osteoarticular lesions compared to the control group.
- Symptom improvement correlated inversely with plasma beta2m clearance, suggesting a direct therapeutic effect.
Conclusions:
- Selective beta2m absorption therapy demonstrates potential for ameliorating established DRA symptoms.
- This therapeutic approach may also prevent the local development and progression of DRA.
- The precise mechanisms underlying symptom amelioration require further investigation.
